Literature DB >> 10499595

The oral fluoropyrimidines in cancer chemotherapy.

E B Lamont1, R L Schilsky.   

Abstract

A classic example of a rationally developed class of anticancer drugs, the fluoropyrimidines are now the focus of further rational approaches to cancer chemotherapy as they are transformed into oral formulations. Given alone, oral 5-fluorouracil (5-FU) has erratic absorption and nonlinear pharmacokinetics. However, when oral 5-FU is given as a prodrug and/or paired with a dihydropyrimidine dehydrogenase inhibitor, the resultant 5-FU has linear pharmacokinetics that may approximate the less myelosuppressive continuous i.v. infusion schedule of 5-FU administration without the use of infusion catheters and pumps. We review the preclinical and clinical experience of several of the oral fluoropyrimidines.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10499595

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  15 in total

1.  Tegafur and 5-fluorouracil pelvic tissue concentrations in rectal cancer patients receiving preoperative chemoradiation.

Authors:  F A Calvo; A Aldaz; L Zufía; D de la Mata; J Serrano; R García; J A Arranz; A Alvarado; J Giráldez
Journal:  Clin Transl Oncol       Date:  2006-07       Impact factor: 3.405

2.  Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity.

Authors:  G Klement; S Baruchel; J Rak; S Man; K Clark; D J Hicklin; P Bohlen; R S Kerbel
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

3.  Genetic Variations of the DPYD Gene and Its Relationship with Ancestry Proportions in Different Ecuadorian Trihybrid Populations.

Authors:  Camila Farinango; Jennifer Gallardo-Cóndor; Byron Freire-Paspuel; Rodrigo Flores-Espinoza; Gabriela Jaramillo-Koupermann; Andrés López-Cortés; Germán Burgos; Eduardo Tejera; Alejandro Cabrera-Andrade
Journal:  J Pers Med       Date:  2022-06-10

Review 4.  Targeted nanoparticles for colorectal cancer.

Authors:  Bruno A Cisterna; Nazila Kamaly; Won Il Choi; Ali Tavakkoli; Omid C Farokhzad; Cristian Vilos
Journal:  Nanomedicine (Lond)       Date:  2016-08-16       Impact factor: 5.307

5.  Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients.

Authors:  Emmanuelle Comets; Kazumasa Ikeda; Paulo Hoff; Pierre Fumoleau; Jantien Wanders; Yusuke Tanigawara
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-08       Impact factor: 2.745

Review 6.  Applications of heteronuclear NMR spectroscopy in biological and medicinal inorganic chemistry.

Authors:  Luca Ronconi; Peter J Sadler
Journal:  Coord Chem Rev       Date:  2008-01-26       Impact factor: 22.315

Review 7.  Fabrication and Use of Poly(d,l-lactide-co-glycolide)-Based Formulations Designed for Modified Release of 5-Fluorouracil.

Authors:  Nattawut Leelakanok; Sean Geary; Aliasger Salem
Journal:  J Pharm Sci       Date:  2017-10-16       Impact factor: 3.784

Review 8.  Oral cancer treatment: developments in chemotherapy and beyond.

Authors:  V J O'Neill; C J Twelves
Journal:  Br J Cancer       Date:  2002-10-21       Impact factor: 7.640

9.  Genetic variability & chemotoxicity of 5-fluorouracil & cisplatin in head & neck cancer patients: a preliminary study.

Authors:  Dipali Dhawan; Harsha Panchal; Shilin Shukla; Harish Padh
Journal:  Indian J Med Res       Date:  2013-01       Impact factor: 2.375

10.  Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial.

Authors:  E Chu; D Haller; T Cartwright; C Twelves; J Cassidy; W Sun; M W Saif; E McKenna; S Lee; H-J Schmoll
Journal:  Br J Cancer       Date:  2014-02-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.